Ciclazindol
Clinical data
Routes of
administration		Oral
ATC code
  • none
Pharmacokinetic data
MetabolismRenal[1]
Elimination half-life~32 hours[1]
ExcretionUrine, feces[1]
Identifiers
  • 10-(3-chlorophenyl)-3,4-dihydro-2H-pyrimido[1,2-a]indol-10-ol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC17H15ClN2O
Molar mass298.77 g·mol−1
3D model (JSmol)
  • Clc1cccc(c1)C3(O)c4c(N2\C3=N/CCC2)cccc4

Ciclazindol (WY-23409) is an antidepressant and anorectic drug of the tetracyclic chemical class that was developed in the mid to late 1970s, but was never marketed.[2][3] It acts as a norepinephrine reuptake inhibitor, and to a lesser extent as a dopamine reuptake inhibitor.[2][4] Ciclazindol has no effects on the SERT, 5-HT receptors, mACh receptors, or α-adrenergic receptors, and has only weak affinity for the H1 receptor.[4][5][6] As suggested by its local anesthetic properties,[5] ciclazindol may also inhibit sodium channels. It is known to block potassium channels as well.[7][8]

See also

References

  1. ^ a b c Swaisland AJ, Franklin RA, Southgate PJ, Coleman AJ (February 1977). "The pharmacokinetics of ciclazindol (Wy 23409) in human volunteers". British Journal of Clinical Pharmacology. 4 (1): 61–5. doi:10.1111/j.1365-2125.1977.tb00668.x. PMC 1428987. PMID 843425.
  2. ^ a b Ghose K, Rama Rao VA, Bailey J, Coppen A (April 1978). "Antidepressant activity and pharmacological interactions of ciclazindol". Psychopharmacology. 57 (1): 109–14. doi:10.1007/BF00426966. PMID 96461. S2CID 12961802.
  3. ^ Levine S (1979). "A controlled comparative trial of a new antidepressant, ciclazindol". The Journal of International Medical Research. 7 (1): 1–6. doi:10.1177/030006057900700101. PMID 369921. S2CID 28112402.
  4. ^ a b Oh VM, Ehsanullah RS, Leighton M, Kirby MJ (January 1979). "Influence of ciclazindol on monoamine uptake and CNS function in normal subjects". Psychopharmacology. 60 (2): 177–81. doi:10.1007/BF00432290. PMID 106428. S2CID 24199961.
  5. ^ a b Waterfall JF, Smith MA, Gaston WH, Maher J, Warburton G (July 1979). "Cardiovascular and autonomic actions of ciclazindol and tricyclic antidepressants". Archives Internationales de Pharmacodynamie et de Thérapie. 240 (1): 116–36. PMID 507990.
  6. ^ Gardner CR, Wilford AE (January 1980). "The effects of mianserine, amitriptyline, ciclazindol and viloxazine on presynaptic alpha-receptors in isolated rat atria [proceedings]". British Journal of Pharmacology. 68 (1): 184P–185P. doi:10.1111/j.1476-5381.1980.tb10705.x. PMC 2044122. PMID 6244029.
  7. ^ Noack T, Edwards G, Deitmer P, et al. (May 1992). "The involvement of potassium channels in the action of ciclazindol in rat portal vein". British Journal of Pharmacology. 106 (1): 17–24. doi:10.1111/j.1476-5381.1992.tb14286.x. PMC 1907450. PMID 1504725.
  8. ^ Lee K, Khan RN, Rowe IC, et al. (April 1996). "Ciclazindol inhibits ATP-sensitive K+ channels and stimulates insulin secretion in CR1-G1 insulin-secreting cells". Molecular Pharmacology. 49 (4): 715–20. PMID 8609901.


Categories